Europe, where CLD is among the top 12 leading causes of death (Blanchier, Leleu, Peck-Radosavljevic, Valla, & Roudot-Thoraval, 2013; Peery et al., 2012) .
Chronic liver disease encompasses a number of conditions characterized by slow but persistent hepatic inflammation causing fibrosis (scar tissue) in the liver (Schuppan & Afdahl, 2008 ). These conditions include chronic alcohol abuse, hepatitis B or C viral infections, and nonalcoholic fatty liver disease (NAFLD), a disease characterized by accumulation of fat in the liver in association with metabolic syndrome. Chronic inflammation of the liver may lead to cirrhosis, and once cirrhosis has developed, patients eventually die or require liver transplantation because of complications or liver cancer.
The unrelenting formation of fibrosis is fundamental to the process from liver inflammation to development of cirrhosis. The progression has three characteristics: (a) transition to cirrhosis usually takes a very long time (as long as 20Y30 years), (b) does not cause symptoms, and (c) severe fibrosis or cirrhosis cannot be identified reliably with standard laboratory tests (Schuppan & Afdahl, 2008) . Thus, CLD remain unrecognized for many years until patients develop complications or cancer. Fibrosis is reversible in early stages if the etiological factor is identified and removed (Dixon, Bhathal, Hughes, & O'Brien, 2004; Friedman, 2007) . Suppression of the causative factor leads to improved outcomes in all etiologies of CLD (Schuppan & Afdahl, 2008 ). Yet fibrosis is hardly ever reversible when cirrhosis has developed. Therefore, early identification of fibrosis is crucial to improving the outcomes of patients with CLD. Considering the absence of CLD symptoms in initial stages, early identification would require mass screening of general population.
Until very recently, the only method effective for early identification of fibrosis was liver biopsy, a method that is invasive and may induce complications (Bravo, Sheth, & Chopra, 2001) . Few noninvasive methods for early detection of fibrosis have been reported that may be potentially useful tools for mass screening of CLD in the general population (Del Poggio & Colombo, 2009; Martinez, Crespo, Navasa, & Forns, 2011; Nguyen & Talwalkar, 2011) . One of these methods, transient elastography (TE), consists of the evaluation of the amount of scar tissue in the liver by measuring the velocity of propagation of a wave within the liver. Transient elastography has high sensitivity and specificity for detection of presence and degree of fibrosis with accuracy similar to that of liver biopsy (Castera, Forns, & Alberti, 2008; Friedrich-Rust et al., 2008) . The area under the receiver operating curve for significant fibrosis differs slightly among studiesVthe average being 91%. Currently, TE is performed in liver clinics of academic hospitals, either by trained physicians or nurses, for assessment of fibrosis in patients with known CLD. Moreover, a recent study suggests that TE may be useful for screening of CLD (Roulot et al., 2011) . However, because of paucity of studies so far, there is no recommendation yet on the possible use of TE as method of mass screening for CLD (Castera, 2011) . Transient elastography is a simple and painless procedure that is performed in a very short time. A limitation is that measurements can be difficult, or even impossible, in obese patients or those with a narrow intercostal space.
Given the lack of symptoms of CLD, a reasonable approach to identify patients in early stages of fibrosis would be to use TE in primary care. In this regard, nurses could be trained to perform this technique as a method of screening for liver diseases as part of overall health assessment. Training is key to the success of the procedure. The manufacturer offers half-day training courses to learn the basic principles of the procedure and interpret the findings. This training should be complemented with completion of procedures supervised by an operator with extensive experience in TE (Kettaneh et al., 2007) . Patients with positive screens can be referred to specialty care for diagnosis and medical management. In patients with confirmed CLD, nurses may then undertake educational interventions with the aim of halting liver disease progression and improving patient outcomes (e.g., counseling for stopping alcohol consumption in alcohol abusers, weight reduction, and lifestyle changes in patients with obesity and metabolic syndrome). Against this background, a pilot study of the feasibility of using TE to detect CLD in the general population in a primary care nurse consultancy was performed.
Methods

Design and Participants
This pilot feasibility study was conducted in Spain in a public health district of Catalonia, in the city of Mataró, a town with 120,000 inhabitants. Subjects, aged 18Y70 years, were identified randomly from the state health registry using specific software and were invited to participate in the study by phone. Exclusions were past or current history of liver disease and lack of informed consent. Five hundred and two subjects agreed to participate in the study. The study protocol was approved by the institutional review board and fulfilled the current regulations about data confidentiality.
Participants were seen in a nurse consultancy specifically set up for the study. Subjects received detailed information before signing the informed consent. The nurse then followed three steps:
1. Collected patient demographics and history. Weight and height were recorded, and arterial pressure was measured using an automated sphygmomanometer. 2. Collected a blood sample for measurement of transaminases (AST/ ALT), glucose and serum lipids, and serological markers of hepatitis B and C infection. (These first two steps took about 20 minutes per subject.) 3. Performed TE, which took about 10 minutes in most cases.
Transient Elastography
Transient elastography was performed using a commercially available system, Fibroscan (Echosens, Paris, France). The method of TE is discussed in detail elsewhere (Castera et al., 2008) . Briefly, the Fibroscan system transmits a vibration of mild amplitude and low frequency through the liver that induces an elastic shear that propagates within the liver. The speed of the shear wave is measured using pulse-echo ultrasound. The velocity of propagation of the wave correlates directly with the stiffness of the tissue; The harder the tissue, the faster the velocity of the wave. The stiffness is measured in kilopascal (kPa).
The examination is performed with the patient lying flat on his or her back, with his or her right arm above the head. The tip of the probe transducer is placed on the skin between the ribs at the level of the right lobe of the liver. An ultrasound image allows a portion of the liver (approximately 4 cm long) to be located, and then stiffness is measured. The software indicates whether measurement has been successful or not.
The final value reported is the median value of 10 successful measurements. The optimal cutoff value for the diagnosis of significant fibrosis has been suggested to be around 7 kPa, yet optimal cutoffs may vary according to etiological factors (Friedrich-Rust et al., 2008) . In the current study, the cutoff value chosen was 6.8 kPa. This cutoff level was selected because it has a high sensitivity and specificity in the detection of significant liver fibrosis in patients with NAFLD, which was anticipated to be the most prevalent cause of liver disease in this population (Yoneda et al., 2008) .
In this study, two nurses were trained initially with the manufacturer's course, followed by about 250 examinations performed under the supervision of an expert nurse with 5 years of experience in TE working in a liver clinic of a university hospital (CB). Nurses were taught about the technique of performing TE, how to improve the success rate of measurements, and how to interpret the results. The nurse expert in TE (CB) was available to answer questions arising about implementation of the TE methodology during the study.
Subjects with TE values above the cutoff were referred to a liver clinic for further evaluation of their disease. A member of the research group communicated with a hepatologist and received the feedback after the consultation was made.
Statistical Analysis
All data were collected in specifically designed case report forms that were then transferred to a computerized database. Comparison of frequencies was performed with the chi-square test, whereas comparison of means was done with the t test for independent samples. The analysis was performed using the Stata 12.1 for Windows (Stata Corp., College Station, TX).
Results
The baseline characteristics of the population studied are shown in Table 1 . Of 502 patients evaluated, an accurate measurement of liver stiffness was achieved in 495 subjects (98.6%). In only seven patients (1.4%), liver stiffness could not be estimated because of an increased amount of adipose tissue in the abdominal wall. Results are based on the 495 subjects with measurement of liver stiffness available.
Twenty-eight of the 495 subjects (5.7%) had increased liver stiffness (Q6.8 kPa) consistent with significant liver fibrosis, whereas the remaining subjects had normal liver stiffness. The presence of liver disease with fibrosis in subjects with increased liver stiffness was confirmed by a hepatologist using standard diagnostic procedures, including ultrasonography and liver biopsy, in selected cases. Ninety percent of subjects with fibrosis had NAFLD, whereas the remaining 10% had alcoholic liver disease. Surprisingly, no cases of hepatitis C or B infection were found. Communications between the research team and the liver clinic were fluent and timely throughout the study.
Comparisons of baseline characteristics of subjects categorized with normal or elevated liver stiffness, based on the cutoff score of 6.8 kPa, are shown in Tables 2 and 3 . Subjects with increased liver stiffness were more frequently male and older, compared to subjects with normal liver stiffness. Moreover, subjects with increased liver stiffness had findings consistent with greater frequency of metabolic syndrome, including higher glucose and triglycerides concentration, higher body mass index and arterial pressure, and increased waist circumference. As expected, mean AST and ALT levels were higher in subjects with increased liver stiffness.
Discussion
The results of the feasibility study showed that nurses trained in TE could carry out the screening procedure. In this trial, CLD with significant fibrosis was detected in 5.7% of subjects from a cohort randomly selected from the general population without previously apparent liver disease.
A recent study reported the efficacy of a nurse-led intervention using TE in the assessment of fibrosis in patients q Note. N = 495. AST = aspartate aminotransferase; ALT = alanine aminotransferase. a Greater than 21 and 14 drinking units per week in men and women, respectively.
with known or suspected liver disease evaluated in an academic hospital (McCorry et al., 2012) . However, to our knowledge, this is the first nurse-led program so far reported for the screening of CLD in the general population. Several aspects of this intervention deserve comment. First, the intervention was effective, as it was able to identify almost 6% of subjects with previously unknown CLD. The presence of liver disease was later confirmed by standard diagnostic procedures. The possibility of false-negative results (patients with CLD with fibrosis who were not recognized with TE) cannot be ruled out. Nonetheless, it should be pointed out that TE is very sensitive in the detection of liver fibrosis (Castera et al., 2008; Friedrich-Rust et al., 2008; Martínez et al., 2011) . Second, given the lack of alternate effective screening methods of liver fibrosis at present, this nurse-led program for liver disease screening could be easily implemented in primary care because of its simplicity and safety. Third, nurses running this program should be trained in the use of TE to ensure accuracy of the technique.
No recommendations for routine screening for CLD currently exist, but the TE screening procedure appears to meet criteria for screening (Castera, 2011) . If the current results are confirmed in other studies and TE is proven to be cost-effective, this nurse-led program should be implemented in primary care to screen for identification of asymptomatic patients with unrecognized liver diseases. The target population could be reached when patients attend clinics for other preventive or screening services, such as arterial pressure, laboratory checkups, weight control, or even patients walking in for minor health problems (Fabrellas et al., 2011) .
It is important to emphasize that the current study was exclusively aimed at assessing feasibility of a nurse-led program using TE to detect unrecognized CLD in the general population. The study was neither designed to evaluate the effects of nurse educational interventions in improving outcomes nor to assess the cost-effectiveness of this approach. Future studies should be performed to evaluate these issues. This type of nurseled program requires a formal agreement with a liver clinic for referring patients with abnormal results of TE for further evaluation. A last point that deserves a comment is that most patients with unveiled CLDs had NAFLD (Bellentani et al., 2000; Dam-Larsen et al., 2004; Ratziu, Bellentani, Cortez-Pinto, Day, & Marchesini, 2010) . The early diagnosis of this condition may allow nurse educational interventions to improve the metabolic syndrome associated with NAFLD and reduce its negative effects in the liver. A potential limitation of TE is the possibility of unsuccessful measurements in markedly obese patients.
Conclusion
A nurse-led screening program based on TE was conducted, which helped to q identify hidden CLD in 5.7% of subjects with unrecognized CLD from the general population. This type of nurse intervention is feasible and may have a role in screening and identification of CLD in the general population. q
